Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.
Completed · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Lupus Erythematosus, Systemic
In brief
The primary objective of the study is to evaluate the safety, tolerability, and efficacy of 4 weeks intravenous treatment with Cpn10 in subjects with mild to moderate active SLE.
Key facts
- Study ID
- NCT01838694
- Run by
- Invion, Inc.
- People needed
- 30
- Starts
- 2013-07-01
- Expected to finish
- 2015-08-01
- Last updated by the study team
- 2017-01-30
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Abel Buchheim Pharmaceutical Research — Miami, Florida, United States
- Northwestern University School of Medicine — Chicago, Illinois, United States
- Altoona Arthritis and Osteoporosis Center — Altoona, Pennsylvania, United States
- Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Metroplex Clinical Research Center — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.